Why would the FDA approve fast track for a 3rd line treatment of a non-life threatening indication?
From the perspective of a regulatory organisation, surely the risk of shortened trials/ less data, huge potential user base etc far outweighs the benefits of earlier mass usage of what is currently only a pain reduction drug. Definitely apply for it if 08 gives Zilosul a DMOAD designation. Otherwise I honestly can't even see an argument that would be agreeable to the FDA for fast tracking this.
research reports and media, page-2225
-
- There are more pages in this discussion • 2,187 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78837 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36290 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |